Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application ...

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS® (brentuximab vedotin) in combination with ...

Diagnostic models were constructed through random forest algorithm and validated in subgroups. Results We determined the disturbance of systemic immunity caused by HCC and PDAC, and calculated a ...

The symptoms are largely due to the onset of anemia (characterized by the loss of red blood cells) and thrombocytopenia (the loss of blood-clotting ... Karen Raymaakers RN, CON(C) is a certified ...

This excess of white blood cells in the peripheral bloodstream is more typical of leukemia. Early involvement of the bone marrow also is more typical of leukemia. Lymphoma is usually diagnosed with a ...

The results, published in the journal Blood, offer new hope for patients whose lymphoma has returned or has not responded to standard treatments. Lymphoma is the fifth most common cancer in the ...

peripheral T-cell lymphoma, mantle cell lymphoma, B-cell acute lymphoblastic leukemia (B-ALL), marginal zone b-cell lymphoma, soft tissue sarcoma, angioimmunoblastic T-cell lymphoma, large anaplastic ...

Peripheral T-cell lymphoma (PTCL) is an aggressive tumor derived from mature T cells and natural killer cells with an extremely poor prognosis. Ferroptosis is a mechanism of cell death that is ...

Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Follicular Lymphoma ... anaplastic large cell lymphoma, advanced right-sided colon cancer, ...

Nodal marginal zone lymphoma (NMZL) is a rare type of non-Hodgkin lymphoma (NHL). It belongs to a group of non-Hodgkin lymphomas called marginal zone lymphomas (MZL). There are three types: nodal ...

Follicular lymphoma (FL) is a mature lymphoid malignancy derived from germinal center B cells, accounting for approximately 22% of all non-Hodgkin's lymphomas. It is common in middle-aged and older ...